RESEARCH TRIANGLE PARK, N.C., U.S.A. (October 24, 2005)

  Qualyst, Inc. announced today that the patent application on its proprietary B-CLEAR® system has been allowed by the European Patent Office. B-CLEAR® is the only in vitro system for the predictive assessment of hepatic uptake, excretion, biliary clearance, and drug transport. Patents on B-CLEAR® have already issued in the United States, Australia, and New Zealand, with other international patents pending.

  "The allowance of the European B-CLEAR® patent application strengthens Qualyst’s position as a global ADMET technology provider, and represents the latest progress in our rapidly expanding intellectual asset portfolio," said Marc Sedam, Qualyst’s vice president for corporate development. "Our client list continues to expand as drug transport studies become more prevalent, and companies realize the unique and powerful results generated through Qualyst’s technology."

About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualystís products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at www.Qualyst.com or call 919-313-6500.

CONTACT:

Ian J. Mehr
Vice President, Business Development
Qualyst, Inc.
919-313-6507
info[AT]qualyst[DOT]com
www.Qualyst.com